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Circadian rhythms are 24-h oscillations present in most eukaryotes and many
prokaryotes that synchronize activity to the day-night cycle. They are an essential feature
of organismal and cell physiology that coordinate many of the metabolic, biosynthetic,
and signal transduction pathways studied in biology. The molecular mechanism of
circadian rhythm is controlled both by signal transduction and gene transcription as well
as by metabolic feedback. The role of circadian rhythm in cancer cell development and
survival is still not well understood, but as will be discussed in this Review, accumulated
research suggests that circadian rhythm may be altered or disrupted in many human
cancers downstream of common oncogenic alterations. Thus, a complete understanding
of the genetic and metabolic alterations in cancer must take potential circadian rhythm
perturbations into account, as this disruption itself will influence how gene expression and
metabolism are altered in the cancer cell compared to its non-transformed neighbor. It
will be important to better understand these circadian changes in both normal and cancer
cell physiology to potentially design treatment modalities to exploit this insight.
Keywords: circadian rhythm, oncogenes, metabolism, cancer metabolism, molecular clock, oscillation, gene
expression regulation
INTRODUCTION: THE CIRCADIAN CLOCK CONTROLS GENE
EXPRESSION AND METABOLISM
The majority of eukaryotes possess a circadian clock to optimize gene expression and metabolism
to the day-night cycle. Cancer cells may disrupt normal circadian oscillation to release cells from
control of gene expression and metabolism and provide a growth advantage. In mammals, many
familiar processes such a sleep/wakefulness, feeding, blood pressure, and body temperature are
synchronized by the circadian clock (Millar-Craig et al., 1978; Spiteri et al., 1982; Cagnacci et al.,
1992; Bass, 2012). The “central clock” is governed by blue-light sensing in the eye and subsequent
processing in the hypothalamic suprachiasmatic nucleus (Moore and Eichler, 1972; Liu et al., 1997;
Ruby et al., 2002), while “peripheral clocks,” which will be the focus of this Review, are present
in virtually all organs and individual cells in the body, and are synchronized by the central clock
through signals such as hypothalamic-pituitary-directed release of adrenal corticosteroids, but
can also operate independently of central clock input (Buijs et al., 1999). Peripheral clocks are
strongly entrained by the time of feeding, and misalignment of feeding and the central clock has
recently been shown to lead to metabolic syndrome (Mukherji et al., 2015a,b). Synchronization
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of the peripheral clock can be simulated in cell culture by
treatment with the corticosteroid dexamethasone (Balsalobre
et al., 2000), or the simple act of changing culture media (Yeom
et al., 2010), and thus, circadian oscillations are likely common in
most non-transformed cells lines and many cancer lines as well.
The molecular circadian clock is governed by several
feedback loops (Figure 1) that lead to 24-h oscillations of
target gene expression, defined by their amplitude (height),
phase (position), and period (length). Several well-described and
FIGURE 1 | The feedback loops that form the molecular clock. The molecular clock is controlled by the master transcription factor heterodimer CLOCK-BMAL1,
which is regulated by two major negative feedback loops that generate 24-h oscillation of clock activity and target genes (Gallego and Virshup, 2007; Mohawk et al.,
2012). In the first and most important loop, CLOCK-BMAL1 upregulates PER and CRY through binding to E-box DNA elements. Unbound PER and CRY proteins are
phosphorylated by casein kinase 1 ε/δ (CK1ε/δ) and AMPK (AMP-kinase), respectively, to lead to degradation. GSK3 (glycogen synthase kinase 3, not pictured) can
also phosphorylate PER and CRY to promote their degradation (Harada et al., 2005; Iitaka et al., 2005). Otherwise, PER and CRY form a complex with CK1, which
translocates to the nucleus to repress CLOCK-BMAL1 activity. PER and CRY are then eventually degraded in a CK1-dependent manner (not pictured), and the time
delay in the first loop forms an approximately 24-h cycle which is particularly dependent on dynamics of PER regulation (D’alessandro et al., 2015). In the second
loop, CLOCK-BMAL1 upregulates the negative transcription factors REV-ERBα and β (gene names NR1D1 and NR1D2) and the positive transcription factors RORα,β,
or γ (not pictured), which repress or activate BMAL1 (gene name ARNTL) transcription, respectively, through binding to RRE (R-response element) DNA sequences.
The importance of this second loop is underscored by the fact that mice lacking REV-ERBα and β, which form a complex and act together, lack normal circadian gene
oscillation in the liver (Bugge et al., 2012; Cho et al., 2012). Several accessory loops exist; in one that will be highlighted in this review, SIRT1 (sirtuin 1) deacetylase
tunes CLOCK-BMAL1 activity by opposing the histone acetyl-transferase (HAT) activity of CLOCK (Asher et al., 2008; Nakahata et al., 2008, 2009; Ramsey et al.,
2009). SIRT1 is regulated by the metabolite NAD, which in turn is produced by the NAD-salvage enzyme NAMPT (nicotinamide phosphoribosyltransferase), the
rate-limiting enzyme of the NAD salvage pathway involved in NAD recycling and synthesis from dietary nicotinamide or niacin. Together, these primary and accessory
loops lead to the 24-h expression of target genes and oscillation of downstream metabolic processes. Figure reprinted and modified from Altman et al. (2015), with
permission from Elsevier.
detailed mathematical models of this molecular oscillation exist,
which have been used to make predictions about perturbations
of the molecular clock (Leloup and Goldbeter, 2003; Relogio
et al., 2011; Hirota et al., 2012; Kim and Forger, 2012). The best-
characterized organ with respect to circadian rhythm is liver,
where more than 20% of mRNAs oscillate (Panda et al., 2002;
Storch et al., 2002; Ueda et al., 2002; Koike et al., 2012). In the
whole mammal, up to 50% of protein-coding RNAs and 30%
ofnon-coding RNAs oscillate in at least one organ, with the liver,
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kidney, and lung being the most “circadian”; however, there is
little overlap in circadian gene expression between organs, with
only 10 genes oscillating in all examined cell types (Zhang et al.,
2014). Ribosome occupancy of mRNA and protein translation
also demonstrate rhythmicity (Jang et al., 2015; Janich et al., 2015;
Lipton et al., 2015), and thus, circadian rhythm strongly controls
gene expression and translation, though the specific identity of
oscillating genes may vary.
Circadian control of metabolism has been extensively studied
on the level of organs.Many specificmetabolites, including lipids,
amino acids, and glycolytic intermediates, oscillate in mouse
liver and human blood, saliva, and even breath (Dallmann et al.,
2012; Eckel-Mahan et al., 2012; Kasukawa et al., 2012; Martinez-
Lozano Sinues et al., 2014). Anabolic pathways in liver, including
nucleotide biosynthesis and ribosomal biogenesis, also showed
circadian oscillation (Fustin et al., 2012; Jouffe et al., 2013). On
the other hand, appreciation of the oscillation of metabolism
on a cell-autonomous level (as observed in tissue culture) is
just becoming appreciated. Two studies demonstrated that NAD
(nicotinamide adenine dinucleotide) oscillates in cell culture and
liver (Figure 1) (Nakahata et al., 2009; Ramsey et al., 2009),
which controls rhythmic mitochondrial oxidation (Peek et al.,
2013). More recently, we observed in U2OS osteosarcoma cells,
a commonly used model of circadian rhythm, that intracellular
glucose showed circadian oscillation (Altman et al., 2015). This
finding is supported by another study showing oscillation of
NADH/NAD+ ratio in epidermal stem cell culture, which may
reflect oscillation in glucose metabolism (Stringari et al., 2015).
An unbiased metabolomic analysis is still needed to determine
the extent of cell-autonomous metabolic oscillations.
Metabolism itself may also control the clock. Several nearly-
simultaneous studies uncovered that the NAD- and NAMPT-
regulated deacetylase SIRT1 opposes the acetylytansferase
activity of CLOCK protein activity (Doi et al., 2006) to
deacetylate PER2, BMAL1, and histones, leading to alterations in
both phase and amplitude of circadian gene oscillation (Asher
et al., 2008; Nakahata et al., 2008, 2009; Ramsey et al., 2009).
NAD availability may also influence circadian rhythm through
regulation of PARP (poly-ADP-ribose polymerase) to regulate
CLOCK-BMAL1 protein and DNA binding (Asher et al., 2010).
Emerging evidence suggests that glucose availability may affect
circadian rhythm, in part by contributing to O-GlcNAcylation
of PER2 to control its activity (Kaasik et al., 2013; Oosterman
and Belsham, 2016). It has long been observed that cancers
have altered metabolism (Warburg, 1956; Vander Heiden et al.,
2011; Stine and Dang, 2013), and that many cancers may have
disrupted circadian rhythm (Levi et al., 2008); however, the
significance and mechanism of the circadian dysrhythmia in
cancer are poorly understood.
ONCOGENIC ALTERATION OF CIRCADIAN
RHYTHM
Mutations in molecular clock genes, including promoter
methylation, coding region mutation, deletion, or rare
amplification, have been documented at a low frequency
(less than 20% incidence per tumor type) across many different
types of cancer (Cerami et al., 2012; Savvidis and Koutsilieris,
2012; Gao et al., 2013; Uth and Sleigh, 2014). Given that these
mutations disrupt normal oscillation, it has been suggested that
the clock may be tumor suppressive. Many proto-oncogenes
and tumor suppressors are normally under circadian control
(Sahar and Sassone-Corsi, 2009), and so disruption of oscillation
could potentially release these proteins to be constitutively
overexpressed or suppressed. This Review will focus on several
notable examples of oncogenic pathways that are often mutated
in cancer and have a well-described relationship to circadian
rhythm. Given the frequency of mutation in the pathways
detailed below, it can be speculated that many cancers with these
and perhaps other oncogenic mutations have altered or disrupted
circadian rhythm and altered oscillation of gene expression and
metabolism.
RAS
The RAS family of GTP-ases (H-, K-, and N-RAS) is mutated in
many cancers to constitutively activate their GTPase function and
hyperstimulate downstream mitogen-activated kinase (MAPK)
signaling. Oncogenic RAS is known to promote transformation
and altered cell metabolism (Pylayeva-Gupta et al., 2011;
Kimmelman, 2015), and work spanning decades suggests that
wild-type RAS is both influenced by and influences the circadian
clock, and thus, mutated oncogenic RAS may potentially
alter circadian rhythm. RAS is highly conserved among lower
organisms in Animalia, and it was shown in Drosophila that
RAS and the MAPK signaling family mediated circadian rhythm,
and inversely that the MAPK pathway itself was governed by
circadian oscillation (Williams et al., 2001). Further studies in
Drosophila revealed that ERK (a critical downstream target of
RAS) could directly phosphorylate CLOCK and thus increase
the output of clock-controlled genes (CCGs) (Weber et al.,
2006). Similarly, clock-controlled genes were increased by active
RAS in the bread mold Neurospora crassa (Belden et al., 2007).
In mammals, RAS and downstream MAPK signaling oscillate
in neurons and in the liver, suggesting circadian control in
both the central and peripheral clocks (Tsuchiya et al., 2013;
Serchov et al., 2016). Neuronal constitutively activated RAS
dramatically disrupted circadian gene oscillation and mouse
circadian activity through upregulation of CCGs, in a pathway
that was dependent on downstream activity of GSK3β (Serchov
et al., 2016), and another study further implicated RAS in
disruption of CCGs downstream of GSK3 (Spengler et al.,
2009). As discussed in the Figure 1 legend, GSK3 is a regulator
of CRY and PER stability. While little work has been done
to demonstrate this mechanism in cancer, one recent study
identified mutated RAS as a mediator of circadian rhythm
disruption in colon cancer cells, potentially through upregulation
of CRY1 (Relogio et al., 2014). Thus, while strong evidence exists
in multiple organisms and model systems that active RAS can
alter circadian rhythm, specifically by upregulating CCGs, the
potential role in cancer cell metabolism and physiology remains
unclear.
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LKB1/AMPK
The AMP-kinase (AMPK) is an ancient protein complex
conserved in nearly all eukaryotes that responds to metabolic
stress (Hardie, 2014) by sensing increases in the AMP:ATP
ratio, and inhibiting biosynthetic processes while upregulating
catabolic metabolism to restore ATP levels (Hardie and Alessi,
2013). The chief upstream kinase responsible for phosphorylating
and activating AMPK downstream of metabolic stress, LKB1
(liver kinase B1), is mutated or lost in many cancers, including
up to 35% of non-small-cell lung carcinomas (Shackelford and
Shaw, 2009). Thus, AMPKmay function as a tumor suppressor in
some cancers, and indeed, AMPK-promoting compounds such
as the widely used complex-I inhibitor metformin and related
biguanides have been investigated in preclinical and clinical
models (Pollak, 2012).
AMPK plays a strong role in controlling circadian rhythm,
and regulates the clock by directly phosphorylating and
promoting the degradation of CRY1 (Lamia et al., 2009), and
promoting the degradation of PER2 through CK1ε activation
(Eide et al., 2005; Um et al., 2007), which both lead to
upregulation of CCGs; however, whether this led to a shortening
or lengthening of the period was unclear. Underscoring
the importance of CK1ε downstream of AMPK, metformin
was shown to upregulate Csnk1 (protein CK1) isoforms in
the mouse and alter oscillation of circadian and metabolic
genes (Barnea et al., 2012). In a separate pathway, AMPK
increases NAD+ levels to activate SIRT1, leading to additional
clock modulation (Fulco et al., 2008; Canto et al., 2009;
Um et al., 2011; Brandauer et al., 2013). Cancer treatments
that activate AMPK, including metformin or anti-metabolic
therapies such as the lactate dehydrogenase A inhibitor FX11
(Le et al., 2010), would be expected to alter the molecular
clock in affected cells. Strikingly, loss of either LKB1 or
of both catalytic subunits of AMPK completely abrogated
circadian oscillation, even in the absence of metabolic stress,
in several models such as MEFs or mouse liver (Lamia
et al., 2009; Um et al., 2011). This raises two interesting
possibilities: first that AMPK is an integral accessory regulator
of the circadian clock, and second, that cancers deficient in
AMPK activity through loss of LKB1 may have a deficient
clock.
p53
The p53 tumor suppressor protein is mutated or lost in a large
number of cancers, leading to dysregulation of metabolism, cell
cycle, and apoptosis (Berkers et al., 2013; Chen, 2016). Recent
evidence suggests an interdependent relationship exists between
p53 and PER2, which has fascinating implications for circadian
rhythm andmetabolism. PER2may directly regulate p53 activity:
inactivation of PER2 bymutation delayed p53 accumulation after
ionizing radiation, sensitizing mice to both cancer development
and death (Fu et al., 2002). Supporting these data, two studies
showed that high levels of PER2 in cancer cell lines and glioma
xenografts correlated with increased p53 induction and apoptosis
(Hua et al., 2006; Zhanfeng et al., 2016). However, the possible
molecular mechanism of p53 activity regulation by PER2 was not
well described in these studies.
This relationship is bidirectional, as p53 can influence PER2
both at the gene expression and protein level. p53 can antagonize
PER2 expression by directly binding to the PER2 promoter
and blocking CLOCK-BMAL1 transactivation of the gene (Miki
et al., 2013). Either loss of p53 or accumulation of p53 protein
caused phase shifts in mouse circadian behavior, suggesting that
both basal and induced p53 can regulate the clock through
PER2 modulation. Adding another layer of complexity, two
complementary studies demonstrated that PER2 protein can
form a dimer with p53 in the cytoplasm to stabilize p53 and
allow translocation to the nucleus, either under basal conditions
or genotoxic stress (Gotoh et al., 2014, 2015). Once in the nucleus,
PER2-p53 also binds its E3 ubiquitin ligase MDM2 (mouse
double minute 2 homolog), and this trimeric complex prevents
p53 ubiquitination and degradation, allowing for increased
transactivation of p53 targets. The authors hypothesized that
PER2 may exist in two pools: one bound to p53, and one bound
to CRY and CK1ε for control of circadian rhythm and subsequent
degradation (Gallego and Virshup, 2007).
Several interesting conclusions can be made from the above
findings. First, given that PER2 strongly controls p53 gene
expression, stability, and localization, and that PER2 levels
oscillate in the cell, wild-type p53 protein and activity itself
must oscillate, making these cells more or less sensitive to DNA
damage at certain times. p53 mRNA and protein oscillation
was observed in several studies (Horiguchi et al., 2013; Miki
et al., 2013), and in fact, circadian sensitivity to p53 activity was
demonstrated in several older studies that identified circadian
variation in radiation toxicity in rodents (Pizzarello et al.,
1964; Lappenbusch, 1972). However, it remains unclear whether
oscillation of p53 activity was due to TP53 mRNA oscillation, or
oscillation of the upstream E3 ubiquitin ligase MDM2 to control
p53 protein stability (Horiguchi et al., 2013). Since p53 feeds back
to suppress PER2 expression and alter protein localization, the
above pathway may be an as-of-yet uncharacterized accessory
loop of endogenous clock control. Additionally, it has been
appreciated in recent years that DNA damage induces oscillatory
p53 activity and protein levels, with a period of about 6 h and
dependent on phosphorylation of both p53 and MDM2 (Lahav
et al., 2004; Geva-Zatorsky et al., 2010). It is likely that, after DNA
damage, this inherent p53 oscillation, circadian control of p53,
and p53 control of PER2 interact in some significant way, but this
has not yet been studied.
Another upshot of this relationship is that altered p53 status
should disrupt circadian oscillation. DNA damage and other
insults induce and stabilize p53 (Chen, 2016), and p53 can control
circadian rhythm through its modulation of PER2 transcription,
protein stability, and protein localization (Miki et al., 2013; Gotoh
et al., 2014, 2015), so it can be hypothesized that under stress
p53 induction will dramatically alter the circadian clock through
its modulation of PER2, which may perhaps be an adaptive
pro-survival process. On the other hand, p53 mutation loss or
mutation in cancer would dramatically affect circadian rhythm,
both by allowing for increased PER2 gene expression (Miki et al.,
2013) and by altering the availability of PER2 protein to bind
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to other partners such as CRY (Gotoh et al., 2014, 2015). One
interesting question is how mutant p53 that has acquired novel
DNA-binding and transactivation functions would affect PER2
and circadian rhythm (Muller and Vousden, 2013). Thus, loss or
mutation of p53 in cancer may alter or disrupt circadian rhythm,
with unknown consequences to cancer physiology.
MYC
The MYC and related MYCN oncogenes (encoding MYC and
N-MYC) are translocated, amplified, or mutated in many
cancers, and can dramatically upregulate genes involved in
glucose and glutamine metabolism, ribosomal, lipid, and
nucleotide biogenesis, and cell cycle progression (Stine et al.,
2015). Given that MYC recognizes and binds to E-Box
DNA promoter elements identical to those recognized by
CLOCK-BMAL1, it was theorized that CLOCK-BMAL1 could
bind to MYC target genes (Fu et al., 2002; Fu and Lee,
2003), an idea later borne out by observation that CLOCK-
BMAL1 could inhibit N-MYC-dependent gene transactivation
(Kondratov et al., 2006). Given that the MYC gene itself
contains multiple E-box elements (Battey et al., 1983), it
was shown that CLOCK-BMAL1 regulates endogenous MYC
circadian oscillation and oscillation of MYC-target genes, both
by direct BMAL1 binding to the MYC promoter, as well
as by additional translational and posttranslational control
by the molecular clock machinery (Fu et al., 2002, 2005;
Okazaki et al., 2010; Repouskou et al., 2010; Repouskou and
Prombona, 2016). It is also likely that endogenous MYC
influences the clock, but this potential role has not been
elucidated.
Given that MYC rewires the cell for altered metabolism and
growth, we hypothesized that hyperactivated oncogenic MYC
could disrupt the molecular clock and thus alter circadian
oscillation of metabolism. We found that overexpressed MYC
and N-MYC upregulated many clock family members, including
PER2, CRY1, and most notably, REV-ERBα (Altman et al., 2015),
leading to a dramatic suppression of BMAL1 expression and
oscillation, which could be rescued by knockdown of REV-
ERBα and its binding partner REV-ERBβ (Bugge et al., 2012;
Altman et al., 2015). Our study also showed that oncogenic
MYC dramatically altered and disrupted circadian oscillation
of glucose and AMPK phosphorylation (Altman et al., 2015),
thus suggesting that oncogenic mutation may disrupt circadian
gene expression, metabolic oscillations, and oscillation of cellular
bioenergetics.
FIGURE 2 | Interdependent relationship of oncogenesis, metabolism, and the circadian clock. Oncogenesis (defined as hyperactivation of pro-growth
pathways downstream of mutations or alterations in RAS or MYC, or loss of normal function in growth-suppressive pathways as p53 or LKB1/AMPK, that lead to
uncontrolled cell growth and transformation) is well known to alter cell metabolism, and these metabolic changes are necessary to support oncogenesis (Hirschey
et al., 2015). As discussed in the Introduction, circadian rhythm strongly influences metabolism, and several metabolic pathways can feed back to control circadian
rhythm. This Review demonstrates that oncogenic pathways, such as RAS, LKB1/AMPK, p53 (in part through p53 regulation of PER2), or MYC (in part through MYC
activation of REV-ERBα), may disrupt or alter the normal peripheral circadian clocks of organs and individual cells. On the other hand, it has been shown that
endogenous RAS, p53 (through PER2 regulation), and MYC oscillate on the genetic and functional level, and so it has been suggested that the clock itself is tumor
suppressive (by regulating these oncogenes and tumor suppressors) and thus can prevent oncogenesis. What is still unknown is the extent to which altered
metabolism downstream of cancer (and pathways such as RAS, LKB1/AMPK, p53, and MYC) contributes to suppression of the molecular clock. Red slash indicates
pathways and proteins that are often lost in cancer, making them tumor-suppressive pathways.
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Interestingly, MYC alteration of circadian gene expression
seems to be highly cell-type specific. For instance, a recent
study in HEK-293 and colon cancer cells showed that
overexpressed MYC bound the PER1 promoter exclusively,
and rather than transactivating expression, this binding led
to a downregulation of PER1 due to competitive inhibition of
CLOCK-BMAL1 promoter occupancy, which would presumably
also lead to circadian disruption (Repouskou and Prombona,
2016). Alternately, MYC overexpression in embryonic stem cells
led to PER cytoplasmic accumulation rather than upregulation
(Umemura et al., 2014). Another study identified CSNK1e
(protein CK1ε) as a synthetic lethal target of MYC and N-
MYC upregulated in neuroblastoma and other human cancers
(Toyoshima et al., 2012), and upregulation of CK1ε would
be expected to destabilize the clock through its promotion
of PER degradation and activation of BMAL1 (Gallego and
Virshup, 2007). It remains to be determined in what contexts
overexpressed MYC in cancer deregulates clock genes through
either promoter co-occupancy, competition with CLOCK-
BMAL1 to trasactivate or repress target genes, or through
forming novel complexes with either CLOCK or BMAL1.
Nonetheless, all of the above studies documented a role for
overexpressed MYC in disruption of circadian oscillation, which
as we showed has consequences for metabolic oscillation and cell




CIRCADIAN RHYTHM, WITH AN EYE
TOWARD CHRONOTHERAPY
Circadian rhythm is an essential part of cell physiology
that underlies many biological processes. Common pathways
involved in oncogenesis alter the molecular clock through
a diverse set of mechanisms, and RAS, p53, and MYC are
strongly regulated by the circadian machinery, suggesting a deep
interdependent relationship that is lost when these genes are
altered in cancer. The manner by which circadian oscillation is
altered is varied: active RAS causes increases in amplitude, p53
loss causes phase shifts, and MYC seems to cause a suppression
of overall oscillation. Adding another layer of complexity, both
oncogenic alterations and circadian rhythm regulate metabolism,
and metabolism itself can feed back to control circadian rhythm.
An interesting consequence is that oncogenic alterations can
potentially disrupt circadian rhythm both through direct effects
on gene expression and protein regulation, and also through
alteration of metabolism (Figure 2). However, the potential role
of altered cancer metabolism in disruption of circadian rhythm
has not been addressed. Additionally, it is not clear how potential
oncogenic alterations of circadian rhythm respond to or modify
synchronizing signals from the central clock.
Several unanswered questions arise from the work reviewed
here. First, why do many cancers potentially disrupt circadian
rhythm? One can imagine that circadian oscillation, which
imposes a “rest” phase every 24 h, is maladaptive to cancer
cells, and so altering or destroying this rhythm might
allow transformed cells to outcompete their non-transformed
neighbors. The clock may be upstream of normal tumor
suppressors and proto-oncogenes (Sahar and Sassone-Corsi,
2009) to regulate normal metabolism and growth, and as shown
above, these pathways seem to form feedback mechanisms with
the clock that are lost in cancer, perhaps releasing oncogenes,
tumor suppressors, and even metabolism from circadian
control.
Second, how can the cancer research community use this
knowledge of circadian disruption to better treat cancer? The
answer may lie in chronotherapy, or timed administration of
treatment to patients, based on circadian rhythm, to increase
efficacy and reduce toxicity of drugs or radiation. Dozens of
traditional cancer therapeutics, including the anti-metabolite
folate pathway antagonist methotrexate, have known circadian-
dependent toxicity (Levi et al., 2010). Excitingly, recent research
indicates that several targeted therapies currently in clinical use
have strongly circadian-dependent efficacy depending on the
time of day given, including but not limited to erlotibin (inhibits
EGFR, used in lung cancer), lapatinib (inhibits HER/Neu and
EGFR, used in breast cancer), and evirolimus (inhibits mTOR,
used in some breast cancers and pancreatic neuroendocrine
tumors), and in fact there are several chronotherapy dosing
schedules under clinical trial (Dallmann et al., 2016). Better
knowledge of how specific oncogenes disrupt normal oscillation
of tumor cells could lead to more effective strategies in delivery
of targeted or metabolic therapies. Circadian disruption is
potentially an essential part of the evolution of cancer, and further
study will allow us to better understand both the benefits to
cancer of this disruption, and how this knowledge can be used
to help patients.
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